

福島県立医科大学 学術機関リポジトリ



Title	臨床研究教育推進部(論文・著書・発表等)
Author(s)	
Citation	福島県立医科大学業績集. 29: 476-478
Issue Date	2019-03-19
URL	http://ir.fmu.ac.jp/dspace/handle/123456789/890
Rights	©2019 福島県立医科大学
DOI	
Text Version	publisher

This document is downloaded at: 2023-05-05T10:25:08Z

小島隆生, 植松高史, 岸田悠吾, 齋藤 清. 脳底動脈閉塞の合併が疑われた椎骨動脈高度狭窄の 1 例. 脳血管内治療ブラッシュアップセミナー2017; 20170709; 神戸.

小島隆生, 岸田悠吾, 新帯一憲, 齋藤 清. 顔面静脈穿刺にて経静脈的塞栓術を行った海綿静脈洞部硬膜動静脈瘻. 第 33 回 NPO 法人日本脳神経血管内治療学会学術総会; 20171123; 東京.

小島隆生, 植松高史, 川上 裕, 安井敬三, 齋藤 清. 発症時間が不明確な脳主幹動脈急性閉塞に対する経皮的血栓回収術. 第 33 回 NPO 法人日本脳神経血管内治療学会学術総会; 20171124; 東京.

小島隆生, 太田圭祐, 浅井琢美, 植松高史, 安井敬三, 関 行雄, 齋藤 清. 院内発症した脳主幹動脈閉塞症に対する経皮的血栓回収術. 第 76 回社団法人日本脳神経外科学会総会; 20171014; 名古屋.

〔特別講演〕

小島隆生, 佐久間潤, 佐藤 拓, 市川優寛, 齋藤 清. 抗血栓療法に伴う頭蓋内出血について. 第 3 世代 DES からの新たな知見～SYNERGY が拓げる新たな可能性～; 20170622; 福島.

〔その他〕

小島隆生, 小祝 萌, 根本未緒, 長井健一郎, 山ノ井優, 飯島綾子, 伊藤裕平, 蛭田 亮, 嶋田裕記, 古川 佑哉, 村上友太, 黒見洋介, 山田昌幸, 佐藤祐介, 岩楯兼尚, 神宮字伸哉, 市川優寛, 佐藤 拓, 藤井正純, 佐久間潤, 齋藤 清. 脳疾患センター開設と脳血管障害診療について. 第 22 回福島脳血管障害治療研究会; 20170617; 郡山.

臨床研究教育推進部

論 文

〔原 著〕

Miyamoto M, Kurita N, Suemitsu K, Murakami M. Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients. American Journal of Nephrology. 2017; 45(4):356-364.

Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. Clinical Genitourinary Cancer. 2017; 15(5):598-604.

Ishihara H, Yagisawa T, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. *International Journal of Clinical Oncology*. 201702; 22(1):126-135.

Ishihara H, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K. Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. *International Journal of Clinical Oncology*. 201702; 22(1):136-144.

Kondo T, Hara I, Takagi T, Kodama Y, Hashimoto Y, Kobayashi H, Iizuka J, Omae K, Yoshida K, Tanabe K. Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. *International Journal of Clinical Oncology*. 201702; 22(1):145-152.

Takagi T, Kondo T, Tachibana H, Iizuka J, Omae K, Kobayashi H, Yoshida K, Tanabe K. Robot-assisted laparoscopic versus open partial nephrectomy in patients with chronic kidney disease: A propensity score-matched comparative analysis of surgical outcomes. *International Journal of Urology*. 201707; 24(7):505-510.

Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K. Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. *Japanese Journal of Clinical Oncology*. 201703; 47(3):226-232.

Ishihara H, Kondo T, Fukuda H, Yoshida K, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K. Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. *Japanese Journal of Clinical Oncology*. 201712; 47(12):1175-1181.

Kamitani T, Yamamoto Y, Kurita N, Yamazaki S, Fukuma S, Otani K, Sekiguchi M, Onishi Y, Takegami M, Ono R, Konno S, Kikuchi S, Fukuhara S. Longitudinal Association Between Subjective Fatigue and Future Falls in Community-Dwelling Older Adults: The Locomotive Syndrome and Health Outcomes in the Aizu Cohort Study (LOHAS). *Journal of Aging and Health*. 201707; 898264317721825.

Kataoka Y, Yamamoto S, Omae K, Kokubo M, Goto Y, Takada T, Naganuma T, Nishiwaki H, Yajima N. A novel approach of understanding prediction models: TRIPOD framework. *Journal of General and Family Medicine*. 201710; 18(5):319-320.

Kurita N, Hayashino Y, Yamazaki S, Akizawa T, Akiba T, Saito A, Fukuhara S. Revisiting Interdialytic Weight Gain and Mortality Association With Serum Albumin Interactions: The Japanese Dialysis Outcomes and Practice Pattern Study. *Journal of Renal Nutrition*. 201711; 27(6):421-429.

Yokoyama K*, Kurita N*, Fukuma S, Akizawa T, Fukagawa M, Onishi Y, Kurokawa K, Fukuhara S (*co-first authors). Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy. *Nephrology Dialysis Transplantation*. 201705; 32(3):534-541.

Omae K, Tsujimoto Y, Honda M, Kondo T, Tanabe K, Fukuhara S, Furukawa TA. Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. *Oncotarget*. 201709; 8(40):68890-68898.

Omae K, Kondo T, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K. Surgical and Oncologic Outcomes of Laparoscopic Radical Nephrectomy for Non-Metastatic Renal Cancer in Long-Term Dialysis Patients. *Therapeutic Apheresis and Dialysis*. 201702; 21(1):31-37.

Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K. Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. *Urologic Oncology*. 201709; 35(9):539.e9-e16.

Omae K, Fukuma S, Ikenoue T, Kondo T, Takagi T, Ishihara H, Tanabe K, Fukuhara S. Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. *Urologic Oncology*. 201709; 35(9):540.e7-e12.

Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. *Urologic Oncology*. 201709; 35(9):542.e1-e9.

大前憲史. 慢性腎不全における抗がん剤治療とその成績 透析患者の転移性腎癌に対する VEGFR-TKI 治療抵抗後逐次的 mTOR 阻害薬治療の経験 第 61 回日本透析医学会学術集会・総会ワークショップより. *日本透析医学会雑誌*. 201701; 50(1):71-72.

栗田宜明, 脇田貴文, 福原俊一, 柴垣有吾. サステイナブルな患者指導を考える 2 効果的な患者指導のエビデンス作成を目指した尺度開発と検証の実際. *日本透析医学会雑誌*. 201703; 50(3):180-181.

大前憲史. 【新腎・泌尿器癌（上）基礎・臨床研究の進歩】 腎癌 腎癌の治療 手術療法 腎癌手術後の腎機能低下. *日本臨床*. 201708; 75(増刊 6):285-289.

性差医療センター

論文

〔原著〕

Suzuki S, Okutsu M, Suganuma R, Komiya H, Nakatani-Enomoto S, Kobayashi S, Ugawa Y, Tateno H,